DermWAVE
Please check back later for more content.
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Case Report Highlights Rural Care Gaps in Recurrent Merkel Cell Carcinoma
3
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
4
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
5